Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience (Q28085428)

Mette Bohl

series ordinal

2

1 reference

Anne Grethe Schioldan

series ordinal

3

1 reference

language of work or name

1 reference

January 2016

1 reference

1 January 2016

4 references

14 March 2019

24 March 2019

17 November 2019

20 November 2019

5 references

14 March 2019

24 March 2019

17 November 2019

20 November 2019

76

1 reference

issue

1

1 reference

page(s)

41-74

1 reference

Creative Commons Attribution-NonCommercial

copyright license

4 references

14 March 2019

24 March 2019

17 November 2019

20 November 2019

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Different intensities of glycaemic control for pregnant women with pre-existing diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro --> Asp insulin analogues

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

10-year follow-up of intensive glucose control in type 2 diabetes

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Safety of intravenous insulin aspart compared to regular human insulin in patients undergoing ICU monitoring post cardiac surgery: an Indian experience

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Insulin aspart pharmacokinetics: an assessment of its variability and underlying mechanisms.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

One size does not fit all glycemic targets for type 2 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Changes in glycemic control and quality of life in pediatric type 1 diabetics with continuous subcutaneous insulin infusion of insulin aspart following multiple daily injection therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Effects of human insulin and insulin aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Needle-free jet injection of rapid-acting insulin improves early postprandial glucose control in patients with diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Prandial insulin dosing using the carbohydrate counting technique in hospitalized patients with type 2 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabete

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Safety and effectiveness of insulin aspart in Basal-bolus regimens regardless of age: a1chieve study results

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Intrinsic fibrillation of fast-acting insulin analogs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Overall mortality in diabetes mellitus: where do we stand today?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Update on inpatient glycemic control in hospitals in the United States

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Postprandial hyperglycemia and glycemic variability: should we care?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Intensive Glucose Control and Cardiovascular Outcomes in Type 2 Diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Equal metabolic control but superior caregiver treatment satisfaction with insulin aspart in preschool children.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Addressing hyperglycemia from hospital admission to discharge

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Healthcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. Data from a large US managed-care organization

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Postprandial glucose regulation and diabetic complications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

New insulins in the treatment of diabetes mellitus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Clinical pharmacokinetics and pharmacodynamics of insulin aspart

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Design of insulin analogues for meal-related therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Monomeric insulins and their experimental and clinical implications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Safety and efficacy of insulin aspart and soluble human insulin in Type 2 diabetes mellitus.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Compatibility of insulin Lispro, Aspart, and Glulisine with the Solo MicroPump, a novel miniature insulin pump

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 Diabetes treated by means of an insulin pump

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

2 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Injection-meal interval: recommendations of diabetologists and how patients handle it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Impaired absorption of insulin aspart from lipohypertrophic injection sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Targeting postprandial hyperglycaemia in patients with recently diagnosed type 2 diabetes with a fixed, weight-based dose of insulin Aspart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Pharmacokinetics following continuous subcutaneous insulin infusion of insulin aspart with or without initial subcutaneous bolus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Pharmacokinetics of insulin aspart in pump-treated subjects with type 1 diabetes: reproducibility and effect of age, weight, and duration of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Lower incidence of recorded cardiovascular outcomes in patients with type 2 diabetes using insulin aspart vs. those on human regular insulin: observational evidence from general practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 diabetes mellitus on multiple daily injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Treatment of diabetic ketoacidosis with subcutaneous insulin aspart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Continuous subcutaneous insulin infusion attenuated glycemic instability in preschool children with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 insulin pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Precipitation of insulin products used for continuous subcutaneous insulin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Health economics analysis of insulin aspart vs. regular human insulin in type 2 diabetes patients, based on observational real life evidence from general practices in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Antibody response to insulin in children and adolescents with newly diagnosed Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Improved postprandial glycaemic controls with insulin Aspart in type 2 diabetic patients treated with insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

Counter-regulatory hormone responses to spontaneous hypoglycaemia during treatment with insulin Aspart or human soluble insulin: a double-blinded randomized cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0500-0

A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Postprandial glycemic control using insulin aspart with NPH in inadequately controlled diabetics

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4700065

Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine

27 November 2018

1 reference

12 December 2020

Effects of rapid-acting insulin analogues insulin glulisine and insulin aspart on postprandial glycemic excursion with single bout of exercise in patients with type 2 diabetes

1 reference

12 December 2020

Treatment of inpatient hyperglycemia beginning in the emergency department: a randomized trial using insulins aspart and detemir compared with usual care

1 reference

12 December 2020

Action profile of the rapid acting insulin analogue: human insulin B28Asp

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions

1 reference

12 December 2020

Development of insulin antibodies and changes in titers over a long-term period in patients with type 2 diabetes

1 reference

12 December 2020

Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus

1 reference

12 December 2020

Premeal insulin treatment during basal-bolus regimen in young children with type 1 diabetes

1 reference

12 December 2020

Influence of local skin temperature and choice of insulin analog on catheter occlusion rates during continuous insulin infusion: an exploratory study

1 reference

12 December 2020

Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes

1 reference

12 December 2020

A comparison of insulin aspart and regular insulin in elderly patients with type 2 diabetes

1 reference

12 December 2020

A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients

1 reference

12 December 2020

Comparison of effects of insulin aspart three times a day versus insulin detemir once a day on oxidative stress in patients with type 2 diabetes

1 reference

12 December 2020

Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart

1 reference

12 December 2020

Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart

1 reference

12 December 2020

Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in Type 1 diabetes

1 reference

12 December 2020

Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes

1 reference

12 December 2020

Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes

1 reference

12 December 2020

Cost-effectiveness of insulin aspart compared to human insulin in pregnant women with type 1 diabetes in the UK

1 reference

12 December 2020

Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes

1 reference

12 December 2020

Insulin aspart has a shorter duration of action than human insulin over a wide dose-range

1 reference

12 December 2020

Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes

1 reference

12 December 2020

A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study

1 reference

12 December 2020

Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart

1 reference

12 December 2020

Evaluation of insulin antibodies and placental transfer of insulin aspart in pregnant women with type 1 diabetes mellitus

1 reference

12 December 2020

Time-action profile of the insulin analogue B28Asp

1 reference

12 December 2020

Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers

1 reference

12 December 2020

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

12 December 2020

The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial

1 reference

12 December 2020

Impact of insulins glulisine and aspart on postprandial glycemia after a high-glycemic index meal in children with type 1 diabetes

1 reference

12 December 2020

10.1007/S40265-015-0500-0

Identifiers

DOI

0 references

Dimensions Publication ID

0 references

1 reference

PubMed publication ID

26607485

1 reference